
Vol. 19, No. 4, 2005
Free Abstract
Article (Fulltext)
Article (PDF 119 KB)
Original Paper
Bendrofluazide Fails to Reduce Elevated Blood Pressure Levels in the Immediate Post-Stroke Period
Penelope J. Eamesa, Thompson G. Robinsona, Ronney B. Paneraib, John F. Pottera
aUniversity of Leicester, Department of Cardiovascular Sciences, Ageing and Stroke Medicine Group, The Glenfield Hospital, Leicester, and bDivision of Medical Physics, University of Leicester, Leicester Royal Infirmary, Leicester, UK
Address of Corresponding Author
Cerebrovasc Dis 2005;19:253-259 (DOI: 10.1159/000084089)
Key Words
- Stroke
- Cerebral autoregulation
- Bendrofluazide
- Blood pressure
Abstract
Introduction: Blood pressure (BP) levels, beat-to-beat blood pressure variability, dynamic cerebral autoregulation and cardiac baroreceptor sensitivity are frequently abnormal following acute stroke and are associated with an adverse short- and long-term prognosis. Thiazide diuretics are effective antihypertensive agents in preventing primary and secondary stroke, but their hypotensive and cerebral autoregulatory effects in the immediate post-stroke period have not been studied. Methods: Thirty-seven hypertensive neuroradiologically proven ischaemic stroke patients were randomized in a double-blind, placebo controlled, parallel group study to bendrofluazide 2.5 mg daily or matching placebo, within 96 h of stroke onset, for a 7-day period. Casual and non-invasive beat-to-beat arterial BP levels, cerebral blood flow velocity, ECG and transcutaneous carbon dioxide levels were measured within 70 ± 20 h of cerebral infarction and again 7 days later. Dynamic cerebral autoregulatory indices, pulse interval, BP variability and cardiac baroreceptor sensitivity were also calculated. Results: Small, non-significant falls were seen in casual and beat-to-beat BP levels over the 7-day period in both active and placebo-treated patients with no differences between treatments. No significant changes were seen in dynamic cerebral autoregulation or in cardiac baroreceptor sensitivity during the follow-up in either group. Conclusion: Following acute ischaemic stroke, the standard dose of bendrofluazide at 2.5 mg daily in this study sample did not lower systemic BP levels over the subsequent 7-day period. There was no evidence that bendrofluazide significantly altered cerebral autoregulation or improved cardiac baroreceptor sensitivity post-ictus. Bendrofluazide appears to be an ineffective hypotensive agent at the standard dosage in the initial post-stroke period. Copyright © 2005 S. Karger AG, Basel
Author Contacts
Prof. J.F. Potter University of Leicester, Department of Cardiovascular Sciences Ageing and Stroke Medicine Group, The Glenfield Hospital Leicester, LE3 9QP (UK) Tel. +44 116 2563643, Fax +44 116 2322976, E-Mail penny.eames@UHL-tr.nhs.uk
Article Information
Received: April 26, 2004
Accepted: November 3, 2004
Published online: February 22, 2005
Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 4, Number of References : 26 |
|

|

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service. |
|
|